Olivier Lambotte

Dr. Olivier Lambotte


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ASAudrey Simonaggio
Audrey Simonaggio
Jean Marie MichotJean Marie Michot
Jean Marie Michot
AVAnne Laure Voisin
Anne Laure Voisin
JPJérome Le Pavec
Jérome Le Pavec
MCMichael Collins
Michael Collins
OLOlivier Lambotte
Olivier Lambotte
Marketing authorizations granted by the European Medicines Agency and the US Food and Drug Administration have made immunotherapy a standard of care in cancer treatment. Along with the initially validated indications (metastatic melanoma,1-3 adjuvant treatment,4,5 and metastatic non–small cell lung cancer6-8) for the immune checkpoint inhibitors (ICIs) of anti–cytotoxic T-lymphocyte antigen-4 (CTLA-4), anti–PD-1 (programmed cell death 1), and anti–PD-L1 (programmed death 1 ligand 1), favorable response rates and survival rates have been observed for many other types of cancer, such as advanced renal cell carcinoma,9,10 metastatic urothelial cancer,11 relapsed or refractory Hodgkin lymphoma,12 and mismatch repair–deficient colorectal cancer.13

15 May 2009 in AIDS
Verified
Journal Article
Closed access
OLOlivier Lambotte
Olivier Lambotte
GFGuido Ferrari
Guido Ferrari
CMChristiane Moog
Christiane Moog
NYNicole L Yates
Nicole L Yates
HLHua-Xin Liao
Hua-Xin Liao
JDJean-François Delfraissy
Jean-François Delfraissy
Objective: To determine the spectrum of antiviral antibodies in HIV-1-infected individuals in whom viral replication is spontaneously undetectable, termed HIV controllers (HICs). Design: Multicenter French trial ANRS EP36 studying the viral control in HICs. Methods: Neutralizing Antibody (nAb) activities (neutralization assay, competition with broadly reactive monoclonal antibodies, and reactivity against the viral MPER gp41 region), FcγR-mediated antiviral activities, antibody-dependent cell cytotoxicity (ADCC), as well as autoantibody levels, were quantified in plasma from 22 controllers and from viremic individuals. The levels of these different antibody responses and HIV-specific CD8 T cell responses quantified by enzyme-linked immunosorbent spot (ELISPOT) IFNγ assay were compared in each controller. Results: The levels of antibody against the gp120 CD4 binding site, gp41, as well as Env epitopes near to the sites bound by broadly nAbs 2F5 and 1b12 were not different between HICs and viremic individuals. We did not find significant autoantibody levels in HICs. The magnitude and breadth of nAbs were heterogeneous in HICs but lower than in viremic individuals. The levels of nAbs using FcγR-mediated assay inhibition were similar in both groups. Regardless of the type of antibody tested, there was no correlation with HIV-specific CD8 T cell responses. ADCC was detectable in all controllers tested and was significantly higher than in viremic individuals (P < 0.0002). Conclusion: There was no single anti-HIV-1 antibody specificity that was a clear correlate of immunity in controllers. Rather, for most antibody types, controllers had the same or lower levels of nAbs than viremic individuals, with the possible exception of ADCC antibodies.

1 March 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
FDFrançois-Xavier Danlos
François-Xavier Danlos
AVAnne-Laure Voisin
Anne-Laure Voisin
VDValérie Dyevre
Valérie Dyevre
Jean Marie MichotJean Marie Michot
Jean Marie Michot
EREmilie Routier
Emilie Routier
OLOlivier Lambotte
Olivier Lambotte

1 September 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
SBSébastien Le Burel
Sébastien Le Burel
SCStéphane Champiat
Stéphane Champiat
CMChristine Mateus
Christine Mateus
AMAurélien Marabelle
Aurélien Marabelle
Jean Marie MichotJean Marie Michot
Jean Marie Michot
OLOlivier Lambotte
Olivier Lambotte

1 March 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
HPH. Picchi
H. Picchi
CMC. Mateus
C. Mateus
CCchristos chouaid
christos chouaid
BBB. Besse
B. Besse
AMA. Marabelle
A. Marabelle
OLOlivier Lambotte
Olivier Lambotte

20 February 2014 in AIDS
Verified
Journal Article
Closed access
NNNicolas Noel
Nicolas Noel
FBFaroudy Boufassa
Faroudy Boufassa
CLCamille Lécuroux
Camille Lécuroux
ASAsier Saez-Cirion
Asier Saez-Cirion
CBChristine Bourgeois
Christine Bourgeois
OLOlivier Lambotte
Olivier Lambotte
Background: Although HIV controllers (HICs) achieve long-term control of viremia in the absence of antiretroviral therapy (ART), they display marked immune activation. The levels of inflammatory biomarkers in HICs and the biomarkers’ relationships with immunologic and virologic status have yet to be fully characterized. Design: A cohort study. Methods: Plasma levels of seven biomarkers [tumor necrosis factor (TNF)α, interleukin (IL)6, IL10, interferon gamma-induced protein 10 (IP10), monocyte chemoattractant protein-1 (MCP1), soluble CD14 (sCD14), soluble CD163 (sCD163)] were compared in 70 HICs, 33 HIV-1-infected, treatment-naive noncontrollers (viremic patients), 30 ART-treated patients and 40 healthy donors. In HICs, we investigated the interplay between biomarkers, cell activation and the CD4+ T-cell count. Results: HICs had higher levels of IP10, TNFα and sCD14 than healthy donors did (P < 0.01 for each). Also, TNFα and sCD14 levels of the HICs were similar to those measured in viremic and ART-treated patients. However, the levels of IL6 and IL10 were significantly lower in HICs than in viremic or ART-treated patients. In HICs, only IP10 levels differed significantly from those in both healthy donors and viremic patients, and were positively correlated with the expression of CD8+ and CD4+ T-cell activation markers. The IP10 levels of HICs were still elevated 12 and 24 months after the initial assay. Lastly, IP10 levels at enrollment were negatively correlated with the CD4+ T-cell count at enrollment and 12 months later. Conclusion: HICs display a number of inflammatory features associated with persistent T-cell immune activation.